www.torontorehab.com
FREE 57p illustrated REPORT ISSN 1910-6831
$38 million research grant.
Chief Scientist
Prof G.FERNIE PhD PEng
Yearly FREE Research meeting (2010 at Toronto SHERATON HOTEL)
20.11.10
TORONTO: 4th Int.Congress on EARLY ONSET SCOLIOSIS & GROWING SPINE
(ICEOS)Nov.19/20 SHERATON TORONTO HOTEL.
Chairman:La JOLLA,Ca. San Diego Centre for Spinal Disorders, Prof. B.A.AKBARNIA MD(Tehran)
"THE GROWING SPINE" B.A.AKBARNIA,M.YAZICI,G.H.THOMPSON Eds.2010,630 pp,304 illus.,81 in colour. SPRINGER Euro.180. ISBN 978-3-540-85206-3
Interesting comments on Danish Surgeon H.W.SCHEUERMANN (1877-1960) "Juvenile scoliosis" and German Pathologist C.G.SCHMORL (1861-1932) "nodes".
Chairman:La JOLLA,Ca. San Diego Centre for Spinal Disorders, Prof. B.A.AKBARNIA MD(Tehran)
"THE GROWING SPINE" B.A.AKBARNIA,M.YAZICI,G.H.THOMPSON Eds.2010,630 pp,304 illus.,81 in colour. SPRINGER Euro.180. ISBN 978-3-540-85206-3
Interesting comments on Danish Surgeon H.W.SCHEUERMANN (1877-1960) "Juvenile scoliosis" and German Pathologist C.G.SCHMORL (1861-1932) "nodes".
12.11.10
HemaCAM: HORN IMAGING GmbH & FRAUNHOFER IIS.
Performing blood counts automatically
Press Release 10.11.2010
With the HemaCAM, scientists at the Fraunhofer Institute for Integrated Circuits IIS in Erlangen have developed a system that automates the assessment of blood counts and at the same time improves the quality of the findings. In collaboration with Horn Imaging GmbH the device has been approved in accordance with the Medicinal Product Guidelines. “The core idea was to combine a microscope with digital image processing,” explains Dr. Christian Münzemeyer, group manager for medical image processing at IIS. “Whereas existing methods such as flow cytometry are based on physical measuring methods, the HemaCAM imitates humans.” Like a human eye, a camera looks through the microscope. Image processing software automatically analyzes up to eight abnormal blood smears and provides classification suggestions.
The expert describes the operation of the new diagnosis system, which makes working procedures in the laboratory more efficient: “For this we have trained our system with expert knowledge. The background to this is a database in which every cell has been entered manually. Computer algorithms use this database to analyze and pre-sort the recorded cells. Every abnormal cell can be individually documented, enlarged up to 100 times. The MLS in the laboratory only checks the result, verifies and then approves it. The findings are then fed into the laboratory information system, and the laboratory director can send out the findings.”
More than six years of development time were required to transform the idea into a fully operational series product. Since the beginning of October Horn Imaging GmbH HemaCAM has been marketing the microscopy system and installing it in specialist laboratories throughout Europe. Fraunhofer researchers are already working on further improvements, though, and will present these at Medica 2010. Director of the department of image processing and medical engineering Christian Weigand adds: “What is new is that we have now integrated a slide handling system that permits us to automatically evaluate and analyze up to 200 slides. In addition to this a further software component is an analysis support system for the morphology of the red blood count. This can be used to diagnose types of anemia, for example; at the same time the red blood count provides indications of liver or kidney damage, metabolic diseases and deficiency symptoms.”
Press Release 10.11.2010
With the HemaCAM, scientists at the Fraunhofer Institute for Integrated Circuits IIS in Erlangen have developed a system that automates the assessment of blood counts and at the same time improves the quality of the findings. In collaboration with Horn Imaging GmbH the device has been approved in accordance with the Medicinal Product Guidelines. “The core idea was to combine a microscope with digital image processing,” explains Dr. Christian Münzemeyer, group manager for medical image processing at IIS. “Whereas existing methods such as flow cytometry are based on physical measuring methods, the HemaCAM imitates humans.” Like a human eye, a camera looks through the microscope. Image processing software automatically analyzes up to eight abnormal blood smears and provides classification suggestions.
The expert describes the operation of the new diagnosis system, which makes working procedures in the laboratory more efficient: “For this we have trained our system with expert knowledge. The background to this is a database in which every cell has been entered manually. Computer algorithms use this database to analyze and pre-sort the recorded cells. Every abnormal cell can be individually documented, enlarged up to 100 times. The MLS in the laboratory only checks the result, verifies and then approves it. The findings are then fed into the laboratory information system, and the laboratory director can send out the findings.”
More than six years of development time were required to transform the idea into a fully operational series product. Since the beginning of October Horn Imaging GmbH HemaCAM has been marketing the microscopy system and installing it in specialist laboratories throughout Europe. Fraunhofer researchers are already working on further improvements, though, and will present these at Medica 2010. Director of the department of image processing and medical engineering Christian Weigand adds: “What is new is that we have now integrated a slide handling system that permits us to automatically evaluate and analyze up to 200 slides. In addition to this a further software component is an analysis support system for the morphology of the red blood count. This can be used to diagnose types of anemia, for example; at the same time the red blood count provides indications of liver or kidney damage, metabolic diseases and deficiency symptoms.”
1.11.10
TOMOTHERAPY TREATMENT CENTRES: QUEBEC
Hospitalier de l’Université de Montréal (CHUM)
Hôpital Notre-Dame
1560 rue Sherbrooke Est
Montréal, Québec
H2L 4M1
+1 514 890 8254
Go to the Centre Hospitalier de l’Université de Montréal (CHUM)
websiteCentre Universitaire de Santé McGill
1650 Cedar Avenue
Montreal, Quebec
H3G 1A4
+1 514 934 1934
Go to the Centre Universitaire de Santé McGill website.
Hôpital Notre-Dame
1560 rue Sherbrooke Est
Montréal, Québec
H2L 4M1
+1 514 890 8254
Go to the Centre Hospitalier de l’Université de Montréal (CHUM)
websiteCentre Universitaire de Santé McGill
1650 Cedar Avenue
Montreal, Quebec
H3G 1A4
+1 514 934 1934
Go to the Centre Universitaire de Santé McGill website.
TOMOTHERAPY TREATMENT CENTRES: ONTARIO
TomoTherapy® Treatment Centers - Ontario London Regional Cancer Program
790 Commissioners Road East
London, ON N6A 4L6 Canada
+1 519 685 8600
Go to the London Regional Cancer Program website
The Ottawa Hospital Cancer Centre
Integrated Cancer Program
Division of Radiation Oncology
503 Smyth Road
Ottawa, Ontario
Canada K1H 1C4
+1 613 737 7700 x70205
Go to the The Ottawa Hospital Cancer Centre website
Toronto Sunnybrook Regional Cancer Centre
2075 Bayview Avenue
Toronto, Ontario
Canada M4N 3M5
+1 416 480 5000
Go to the Toronto Sunnybrook Regional Cancer Centre website.
790 Commissioners Road East
London, ON N6A 4L6 Canada
+1 519 685 8600
Go to the London Regional Cancer Program website
The Ottawa Hospital Cancer Centre
Integrated Cancer Program
Division of Radiation Oncology
503 Smyth Road
Ottawa, Ontario
Canada K1H 1C4
+1 613 737 7700 x70205
Go to the The Ottawa Hospital Cancer Centre website
Toronto Sunnybrook Regional Cancer Centre
2075 Bayview Avenue
Toronto, Ontario
Canada M4N 3M5
+1 416 480 5000
Go to the Toronto Sunnybrook Regional Cancer Centre website.
25.10.10
VIRTUAL BRAIN: Toronto BAYCREST (Jewish Home for the Aged) KUNIN-LUNENFELD APPLIED RESEARCH UNIT.
October 22, 2010
For Immediate Release
Baycrest’s virtual brain project receives $6.3M from American foundation
Toronto, Canada – The U.S.-based James S. McDonnell Foundation has awarded $6.3 million in new funding over the next three years to an international project led by Baycrest to create the world’s first functional, virtual brain.
Dr. Randy McIntosh, project leader.
Dr. Randy McIntosh talks about the virtual brain project (video) >
The project puts Canada in a global race to pull off a neuroscience feat that is comparable to decoding the human genome. The new funding is in addition to $7.5 million the prestigious American foundation provided five years ago to help launch the massive endeavour.
“On behalf of Baycrest and our international science team, we are energized by the continuing support and investment from the James S. McDonnell Foundation, who champion transformative research efforts,” said Dr. Randy McIntosh, project leader, senior scientist and vice-president of Research at Baycrest.
“The new funding helps our project move into its second phase and a step closer to creating a predictive modeling tool that will change the way we assess and rehabilitate brains that have suffered damage from stroke, epilepsy, or the early stages of Alzheimer’s.”
Susan Fitzpatrick, vice-president of the James S. McDonnell Foundation said “the Foundation is pleased to be able to contribute to this effort to bring cognitive neuroscience, computational biology, and clinical neurology together in an ambitious attempt to improve our abilities to alter the course of recovery for individuals with brain injuries.”
The project presents a massive informatics challenge that requires a team of scientists from Canada, the U.S., Europe and Australia to upload thousands of patterns of brain imaging data from healthy individuals and patient groups into several large super computers. Once that work is complete, the virtual brain will deliver the same observable measurements or functioning patterns as a real brain.
The implications of this new tool for clinical interventions will be revolutionary. A clinician will be able to upload brain imaging data from their patient’s unique neural architecture after a stroke, for example, into the synthetic healthy brain model to see how it responds to the disruption of normal network patterns and attempts to re-stabilize. This will assist the clinician in determining the treatment interventions that will likely have the best outcomes for their patient.
In addition to the James S. McDonnell Foundation, the Ontario Innovation Trust and Rx&D (Canada's Research-Based Pharmaceutical Companies) are supporting the project.
For Immediate Release
Baycrest’s virtual brain project receives $6.3M from American foundation
Toronto, Canada – The U.S.-based James S. McDonnell Foundation has awarded $6.3 million in new funding over the next three years to an international project led by Baycrest to create the world’s first functional, virtual brain.
Dr. Randy McIntosh, project leader.
Dr. Randy McIntosh talks about the virtual brain project (video) >
The project puts Canada in a global race to pull off a neuroscience feat that is comparable to decoding the human genome. The new funding is in addition to $7.5 million the prestigious American foundation provided five years ago to help launch the massive endeavour.
“On behalf of Baycrest and our international science team, we are energized by the continuing support and investment from the James S. McDonnell Foundation, who champion transformative research efforts,” said Dr. Randy McIntosh, project leader, senior scientist and vice-president of Research at Baycrest.
“The new funding helps our project move into its second phase and a step closer to creating a predictive modeling tool that will change the way we assess and rehabilitate brains that have suffered damage from stroke, epilepsy, or the early stages of Alzheimer’s.”
Susan Fitzpatrick, vice-president of the James S. McDonnell Foundation said “the Foundation is pleased to be able to contribute to this effort to bring cognitive neuroscience, computational biology, and clinical neurology together in an ambitious attempt to improve our abilities to alter the course of recovery for individuals with brain injuries.”
The project presents a massive informatics challenge that requires a team of scientists from Canada, the U.S., Europe and Australia to upload thousands of patterns of brain imaging data from healthy individuals and patient groups into several large super computers. Once that work is complete, the virtual brain will deliver the same observable measurements or functioning patterns as a real brain.
The implications of this new tool for clinical interventions will be revolutionary. A clinician will be able to upload brain imaging data from their patient’s unique neural architecture after a stroke, for example, into the synthetic healthy brain model to see how it responds to the disruption of normal network patterns and attempts to re-stabilize. This will assist the clinician in determining the treatment interventions that will likely have the best outcomes for their patient.
In addition to the James S. McDonnell Foundation, the Ontario Innovation Trust and Rx&D (Canada's Research-Based Pharmaceutical Companies) are supporting the project.
22.10.10
MED-IQ Organizers of CONTINUED MEDICAL EDUCATION
Programs are developed in full compliance with ACCME, OIG, and PhRMA guidelines and we guarantee every program is fair, balanced, independent, and free of commercial bias.
Team Med-IQ
Clinical content team develops programming from a participant perspective. Led by William Mencia, MD, and Rachel Karcher, PharmD, the Med-IQ team has more than 55 years of continuing medical education experience and also includes the clinical expertise of Sara Miller, MS, Allison Gardner, PhD, and Jean Cornish, RPh.
Med-IQ
5523 Research Park Drive
Suite 210
Baltimore, MD 21228
Phone: 866 858 7434
Fax: 866 419 5789
E-mail: info@med-iq.com
Team Med-IQ
Clinical content team develops programming from a participant perspective. Led by William Mencia, MD, and Rachel Karcher, PharmD, the Med-IQ team has more than 55 years of continuing medical education experience and also includes the clinical expertise of Sara Miller, MS, Allison Gardner, PhD, and Jean Cornish, RPh.
Med-IQ
5523 Research Park Drive
Suite 210
Baltimore, MD 21228
Phone: 866 858 7434
Fax: 866 419 5789
E-mail: info@med-iq.com
19.10.10
LOCKMED Medical Product Co. (Aluminium pharmaceutical container)
LOCKMED Medium Combination Lockbox
$20.99 (USA dollars)
LOCKMED SMALL Combination Lockbox
$18.99
LOCKMED LARGE KEY (not combination) Lockbox
$22.99
LOCKMED Medical Product Company
P.O. Box 13166
Pittsburgh, PA 15243
www.lockmed.com
Phone: (888) 458-2746
Email: info@lockmed.com
Carrying handle. WHITE CROSS on RED BACKGROUND DISK. Numbered RETURN FOR REWARD attached plastic label with details to contact TrackItBack service. www.TrackItBack.com.
(Canadian agent: wellbeings www.wellbeings.ca )
$20.99 (USA dollars)
LOCKMED SMALL Combination Lockbox
$18.99
LOCKMED LARGE KEY (not combination) Lockbox
$22.99
LOCKMED Medical Product Company
P.O. Box 13166
Pittsburgh, PA 15243
www.lockmed.com
Phone: (888) 458-2746
Email: info@lockmed.com
Carrying handle. WHITE CROSS on RED BACKGROUND DISK. Numbered RETURN FOR REWARD attached plastic label with details to contact TrackItBack service. www.TrackItBack.com.
(Canadian agent: wellbeings www.wellbeings.ca )
16.10.10
SARCOPENIC OBESITY
Sarcopoenic obesity discussed by Dr. William EVANS,PhD of GlaxoSmithKline,USA at Toronto meeting of American Society for Bone and Mineral Research.
Weight gain in elderly is 100% FAT: weight loss in elderly is 50% MUSCLE mass.
10 days in bed leads to 2K. muscle mass loss.
1% a year muscle mass lost after age 20.
Ann N Y Acad Sci. 2000 May;904:437-48.
Body composition in healthy aging.
Baumgartner RN.
Division of Epidemiology and Preventive Medicine, University of New Mexico School of Medicine, Albuquerque 87131, USA. rbaumgartner@salud.unm.edu
Abstract
Health risks in elderly people cannot be evaluated simply in conventional terms of body fatness or fat distribution. Elderly people have less muscle and bone mass, expanded extracellular fluid volumes, and reduced body cell mass compared to younger adults. These nonfat components of body composition play critical roles, influencing cognitive and physical functional status, nutritional and endocrine status, quality of life, and comorbidity in elderly people. Different patterns of "disordered body composition" have different relationships to these outcomes and may require different, tailored approaches to treatment that combine various exercise regimens and dietary supplements with hormone replacement or appetite-stimulating drugs. Skeletal muscle atrophy, or "sarcopenia," is highly prevalent in the elderly population, increases with age, and is strongly associated with disability, independent of morbidity. Elders at greatest risk are those who are simultaneously sarcopenic and obese. The accurate identification of sarcopenic obesity requires precise methods of simultaneously measuring fat and lean components, such as dual-energy X-ray absorptiometry.
Weight gain in elderly is 100% FAT: weight loss in elderly is 50% MUSCLE mass.
10 days in bed leads to 2K. muscle mass loss.
1% a year muscle mass lost after age 20.
Ann N Y Acad Sci. 2000 May;904:437-48.
Body composition in healthy aging.
Baumgartner RN.
Division of Epidemiology and Preventive Medicine, University of New Mexico School of Medicine, Albuquerque 87131, USA. rbaumgartner@salud.unm.edu
Abstract
Health risks in elderly people cannot be evaluated simply in conventional terms of body fatness or fat distribution. Elderly people have less muscle and bone mass, expanded extracellular fluid volumes, and reduced body cell mass compared to younger adults. These nonfat components of body composition play critical roles, influencing cognitive and physical functional status, nutritional and endocrine status, quality of life, and comorbidity in elderly people. Different patterns of "disordered body composition" have different relationships to these outcomes and may require different, tailored approaches to treatment that combine various exercise regimens and dietary supplements with hormone replacement or appetite-stimulating drugs. Skeletal muscle atrophy, or "sarcopenia," is highly prevalent in the elderly population, increases with age, and is strongly associated with disability, independent of morbidity. Elders at greatest risk are those who are simultaneously sarcopenic and obese. The accurate identification of sarcopenic obesity requires precise methods of simultaneously measuring fat and lean components, such as dual-energy X-ray absorptiometry.
5.10.10
FOLLICULAR UNIT EXTRACTOR for HAIR TRANSPLANTATION
FUE : Follicular Unit Extractor invented by PARIS, Plastic Surgeon PASCAL BOUDJEMA
69 rue de la Tour.
docteur@pascal-boudjema.com
(FUEPK-7000)new model $8,000 from www.bkworldco.com South Korea.
69 rue de la Tour.
docteur@pascal-boudjema.com
(FUEPK-7000)new model $8,000 from www.bkworldco.com South Korea.
4.10.10
SYNOVIS LIFE TECHNOLOGIES,Inc of St.Paul, MN.
SYNOVIS SURGICAL INNOVATIONS (a division of Synovis Life Technologies), synovissurgical.com, presented a conference on the VERITAS COLLAGEN MATRIX,(bovine pericardial xenograft), at the Toronto meeting of the American Association of Plastic Surgeons. Speakers were Michael MEININGER,Beaumont Hospital,Mich.; Mark MOFID,Univ.Calif.,San Diego; Daniel MOORADIAN PhD,Synovis Life Tech.; Donald MORRIS, Harvard Med.School; Martin NEWMAN, Cleveland Clinic, Weston,Fl. Main uses of VERITAS COLLAGEN MATRIX are BREAST RECONSTRUCTION & VENTRAL HERNIA REPAIR. Cost of a large sheet for Ventral repair can be $3,000.
SYNOVIS LIFE TECHNOLOGIES (NASDAQ:SYNO) Shares increased approx 800% since 1985.
SYNOVIS LIFE TECHNOLOGIES (NASDAQ:SYNO) Shares increased approx 800% since 1985.
30.9.10
ANDRIOL (ORGANON NV)
Organon NV (maker of ANDRIOL) was bought by SCHERING.PLOUGH which then merged with MERCK.
In ONTARIO, ANDRIOL is provided FREE to men over 65y (on medical advice).
In ONTARIO, ANDRIOL is provided FREE to men over 65y (on medical advice).
28.9.10
ADDENBROOKE'S Hosp.CAMBRIDGE,UK. ADVICE to PATIENTS on LAPAROSCOPY
Patient Information
Department of Urology
66/Urol_04_09
Laparoscopic removal of the adrenal gland
Page 1 of 7
Laparoscopic removal of the adrenal gland: procedure-specific information What is the evidence base for this information? This leaflet includes advice from consensus panels, the British Association of Urological Surgeons, the Department of Health and evidence-based sources; it is, therefore, a reflection of best practice in the UK. It is intended to supplement any advice you may already have been given by your GP or other healthcare professionals. Alternative treatments are outlined below and can be discussed in more detail with your Urologist or Specialist Nurse. What does the procedure involve? This involves removal of the adrenal gland through several keyhole incisions. It requires placement of a telescope and operating instruments into your abdominal cavity using 3-4 small incisions. One incision may need to be enlarged to remove the adrenal gland What are the alternatives to this procedure? Observation, open surgery
Laparoscopic removal of the adrenal gland
Page 2 of 7
What should I expect before the procedure? You will usually be admitted on the same day as your surgery. You will normally receive an appointment for pre-assessment, approximately 14 days before your admission, to assess your general fitness, to screen for the carriage of MRSA and to perform some baseline investigations. After admission, you will be seen by members of the medical team which may include the Consultant, Specialist Registrar, House Officer and your named nurse. You will be asked not to eat or drink for 6 hours before surgery and, immediately before the operation, you may be given a pre-medication by the anaesthetist which will make you dry-mouthed and pleasantly sleepy. Please be sure to inform your Urologist in advance of your surgery if you have any of the following:
an artificial heart valve
a coronary artery stent
a heart pacemaker or defibrillator
an artificial joint
an artificial blood vessel graft
a neurosurgical shunt
any other implanted foreign body
a prescription for Warfarin, Aspirin or Clopidogrel (Plavix®)
a previous or current MRSA infection
What happens during the procedure? Normally, a full general anaesthetic will be used and you will be asleep throughout the procedure. In some patients, the anaesthetist may also use an epidural anaesthetic which improves or minimises pain post-operatively. A bladder catheter is normally inserted during the operation to monitor urine output and a drainage tube may be placed through the skin into the bed of the adrenal gland.
Laparoscopic removal of the adrenal gland
Page 3 of 7
What happens immediately after the procedure? You will be given fluids to drink from an early stage after the operation and you will be encouraged to mobilise as soon as you are comfortable to prevent blood clots forming in your legs. The wound drain and catheter are normally removed after 24-48 hours. The average hospital stay is 3-5 days. Are there any side-effects? Most procedures have a potential for side-effects. You should be reassured that, although all these complications are well-recognised, the majority of patients do not suffer any problems after a urological procedure. Please use the check boxes to tick off individual items when you are happy that they have been discussed to your satisfaction: Common (greater than 1 in 10) Temporary shoulder tip pain Temporary abdominal bloating Temporary insertion of a bladder catheter and wound drain Conversion to open surgery or requiring blood transfusion (approximately 14%) Occasional (between 1 in 10 and 1 in 50) Bleeding, infection, pain or hernia of the incision requiring further treatment Rare (less than 1 in 50) Entry into lung cavity requiring insertion of a temporary drain The histological abnormality may eventually turn out not to be cancer Recognised (or unrecognised) injury to organs/blood vessels requiring conversion to open surgery (or deferred open surgery) Involvement or injury to nearby local structures (blood vessels, spleen, liver, kidney ,lung, pancreas, bowel) requiring more extensive surgery Anaesthetic or cardiovascular problems possibly requiring intensive care admission (including chest infection, pulmonary embolus, stroke, deep vein thrombosis, heart attack and death) Hospital-acquired infection (overall risk for Addenbrooke’s) Colonisation with MRSA (0.9%, 1 in 110) Clostridium difficile bowel infection (0.2%; 1 in 500) MRSA bloodstream infection (0.08%; 1 in 1,250) (These rates may be greater in high-risk patients e.g. with long-term drainage tubes, after removal of the bladder for cancer, after previous infections, after prolonged hospitalisation or after multiple admissions)
Laparoscopic removal of the adrenal gland
Page 4 of 7
What should I expect when I get home? There may be some discomfort from the small incisions in your abdomen but this can normally be controlled with simple painkillers. All the wounds are closed with absorbable stitches which do not require removal. It will take 10-14 days to recover fully from the procedure and most people can return to normal activities after 2-4 weeks. When you leave hospital, you will be given a “draft” discharge summary of your admission. This holds important information about your inpatient stay and your operation. If, in the first few weeks after your discharge, you need to call your GP for any reason or to attend another hospital, please take this summary with you to allow the doctors to see details of your treatment. This is particularly important if you need to consult another doctor within a few days of your discharge. What else should I look out for? If you develop a temperature, increased redness, throbbing or drainage at the site of the operation, you should contact your GP immediately. Are there any other important points? A follow-up outpatient appointment will normally be arranged for you 6-12 weeks after the operation. At this time, we will be able to inform you of the results of pathology tests on the removed adrenal gland. It will be at least 14-21 days before the pathology results on the tissue removed are available. It is normal practice for the results of all biopsies to be discussed in detail at a multi-disciplinary meeting before any further treatment decisions are made. You and your GP will be informed of the results after this discussion. Your remaining adrenal gland will serve the full function originally carried out by the pair of glands. It is sometimes necessary, however, to take medications to help the remaining gland recover (usually in patients with Cushing’s syndrome). If both glands have to be removed (this is very rare), medications will need to be taken to replace their function. Is there any research being carried out in this field at Addenbrooke’s Hospital? All laparoscopic procedures are subject to continuous audit by the British Association of Urological Surgeons Section of Endourology. In addition, the National Institute of Health & Clinical Excellence (NICE) requires that we maintain a careful review of laparoscopic procedures.
Department of Urology
66/Urol_04_09
Laparoscopic removal of the adrenal gland
Page 1 of 7
Laparoscopic removal of the adrenal gland: procedure-specific information What is the evidence base for this information? This leaflet includes advice from consensus panels, the British Association of Urological Surgeons, the Department of Health and evidence-based sources; it is, therefore, a reflection of best practice in the UK. It is intended to supplement any advice you may already have been given by your GP or other healthcare professionals. Alternative treatments are outlined below and can be discussed in more detail with your Urologist or Specialist Nurse. What does the procedure involve? This involves removal of the adrenal gland through several keyhole incisions. It requires placement of a telescope and operating instruments into your abdominal cavity using 3-4 small incisions. One incision may need to be enlarged to remove the adrenal gland What are the alternatives to this procedure? Observation, open surgery
Laparoscopic removal of the adrenal gland
Page 2 of 7
What should I expect before the procedure? You will usually be admitted on the same day as your surgery. You will normally receive an appointment for pre-assessment, approximately 14 days before your admission, to assess your general fitness, to screen for the carriage of MRSA and to perform some baseline investigations. After admission, you will be seen by members of the medical team which may include the Consultant, Specialist Registrar, House Officer and your named nurse. You will be asked not to eat or drink for 6 hours before surgery and, immediately before the operation, you may be given a pre-medication by the anaesthetist which will make you dry-mouthed and pleasantly sleepy. Please be sure to inform your Urologist in advance of your surgery if you have any of the following:
an artificial heart valve
a coronary artery stent
a heart pacemaker or defibrillator
an artificial joint
an artificial blood vessel graft
a neurosurgical shunt
any other implanted foreign body
a prescription for Warfarin, Aspirin or Clopidogrel (Plavix®)
a previous or current MRSA infection
What happens during the procedure? Normally, a full general anaesthetic will be used and you will be asleep throughout the procedure. In some patients, the anaesthetist may also use an epidural anaesthetic which improves or minimises pain post-operatively. A bladder catheter is normally inserted during the operation to monitor urine output and a drainage tube may be placed through the skin into the bed of the adrenal gland.
Laparoscopic removal of the adrenal gland
Page 3 of 7
What happens immediately after the procedure? You will be given fluids to drink from an early stage after the operation and you will be encouraged to mobilise as soon as you are comfortable to prevent blood clots forming in your legs. The wound drain and catheter are normally removed after 24-48 hours. The average hospital stay is 3-5 days. Are there any side-effects? Most procedures have a potential for side-effects. You should be reassured that, although all these complications are well-recognised, the majority of patients do not suffer any problems after a urological procedure. Please use the check boxes to tick off individual items when you are happy that they have been discussed to your satisfaction: Common (greater than 1 in 10) Temporary shoulder tip pain Temporary abdominal bloating Temporary insertion of a bladder catheter and wound drain Conversion to open surgery or requiring blood transfusion (approximately 14%) Occasional (between 1 in 10 and 1 in 50) Bleeding, infection, pain or hernia of the incision requiring further treatment Rare (less than 1 in 50) Entry into lung cavity requiring insertion of a temporary drain The histological abnormality may eventually turn out not to be cancer Recognised (or unrecognised) injury to organs/blood vessels requiring conversion to open surgery (or deferred open surgery) Involvement or injury to nearby local structures (blood vessels, spleen, liver, kidney ,lung, pancreas, bowel) requiring more extensive surgery Anaesthetic or cardiovascular problems possibly requiring intensive care admission (including chest infection, pulmonary embolus, stroke, deep vein thrombosis, heart attack and death) Hospital-acquired infection (overall risk for Addenbrooke’s) Colonisation with MRSA (0.9%, 1 in 110) Clostridium difficile bowel infection (0.2%; 1 in 500) MRSA bloodstream infection (0.08%; 1 in 1,250) (These rates may be greater in high-risk patients e.g. with long-term drainage tubes, after removal of the bladder for cancer, after previous infections, after prolonged hospitalisation or after multiple admissions)
Laparoscopic removal of the adrenal gland
Page 4 of 7
What should I expect when I get home? There may be some discomfort from the small incisions in your abdomen but this can normally be controlled with simple painkillers. All the wounds are closed with absorbable stitches which do not require removal. It will take 10-14 days to recover fully from the procedure and most people can return to normal activities after 2-4 weeks. When you leave hospital, you will be given a “draft” discharge summary of your admission. This holds important information about your inpatient stay and your operation. If, in the first few weeks after your discharge, you need to call your GP for any reason or to attend another hospital, please take this summary with you to allow the doctors to see details of your treatment. This is particularly important if you need to consult another doctor within a few days of your discharge. What else should I look out for? If you develop a temperature, increased redness, throbbing or drainage at the site of the operation, you should contact your GP immediately. Are there any other important points? A follow-up outpatient appointment will normally be arranged for you 6-12 weeks after the operation. At this time, we will be able to inform you of the results of pathology tests on the removed adrenal gland. It will be at least 14-21 days before the pathology results on the tissue removed are available. It is normal practice for the results of all biopsies to be discussed in detail at a multi-disciplinary meeting before any further treatment decisions are made. You and your GP will be informed of the results after this discussion. Your remaining adrenal gland will serve the full function originally carried out by the pair of glands. It is sometimes necessary, however, to take medications to help the remaining gland recover (usually in patients with Cushing’s syndrome). If both glands have to be removed (this is very rare), medications will need to be taken to replace their function. Is there any research being carried out in this field at Addenbrooke’s Hospital? All laparoscopic procedures are subject to continuous audit by the British Association of Urological Surgeons Section of Endourology. In addition, the National Institute of Health & Clinical Excellence (NICE) requires that we maintain a careful review of laparoscopic procedures.
24.9.10
TREATMENT EPSTEIN-BARR VIRUS (HHV-4)
An update on the management of glandular fever (infectious mononucleosis) and its sequelae caused by Epstein–Barr virus (HHV-4): new and emerging treatment strategies
(95) Article views
Authors: A Martin Lerner, Safedin H Beqaj, Ken Gill, et al
Published Date September 2010 , Volume 2010:2 Pages 135 - 145 DOI 10.2147/VAAT.S6749
A Martin Lerner1, Safedin H Beqaj2, Ken Gill3, James Edington3, James T Fitzgerald4, Robert G Deeter5
1Department of Medicine, William Beaumont Hospital, Royal Oak, MI, USA; 2DCL Medical Laboratories, Indianapolis, IN, USA; 3The Dr A Martin Lerner, Chronic Fatigue Syndrome Foundation, Beverly Hills, MI, USA; 4Department of Medical Education, University of Michigan, Medical School, Ann Arbor, MI, USA; 5Hematology-Oncology, Global Health Economics, Amgen Inc, Thousand Oaks, CA, USA
Purpose: Beginning in 1993 at a single chronic fatigue syndrome (CFS) treatment center, we began studies that demonstrate Epstein–Barr virus (EBV) nonpermissive replication. In the most recent study performed, EBV nonpermissive replication is the cause of 28.3% of 106 consecutive CFS cases, and is etiologic with human cytomegalovirus (HCMV) and/or human herpes virus 6 (HHV-6) as a coinfection in an additional 52.8% of CFS cases. Therefore, EBV is causally involved in 81% of cases of CFS. Further, EBV CFS is effectively treated with long-term valacyclovir. Coinfection HCMV and HHV-6 CFS requires valganciclovir with valacyclovir.
Patients and results: The validated Energy Index Point Score® (EIPS®) monitors severity of CFS illness and its recovery. A specific CFS diagnostic panel identifies EBV CFS subsets. Four separate EBV CFS therapeutic studies of several hundred CFS patients describe valacyclovir (VALTREX) administration and long-term patient recovery. With valacyclovir, serum EBV titers (EBV, early antigen (diffuse); EBV, viral capsid antigen, immunoglobulin M); 24-hour electrocardiography Holter monitors; and cardiac dynamic studies improve.
Conclusion: Nonpermissive EBV infection is causal in a significant proportion of CFS cases. EBV CFS is safely and effectively treated with long-term valacyclovir.
Keywords: valacyclovir (VALTREX) treatment, chronic fatigue syndrome, Epstein–Barr virus, EIPS, Energy Index Point Score
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Other articles by Dr Ann Cavanagh
Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome
(95) Article views
Authors: A Martin Lerner, Safedin H Beqaj, Ken Gill, et al
Published Date September 2010 , Volume 2010:2 Pages 135 - 145 DOI 10.2147/VAAT.S6749
A Martin Lerner1, Safedin H Beqaj2, Ken Gill3, James Edington3, James T Fitzgerald4, Robert G Deeter5
1Department of Medicine, William Beaumont Hospital, Royal Oak, MI, USA; 2DCL Medical Laboratories, Indianapolis, IN, USA; 3The Dr A Martin Lerner, Chronic Fatigue Syndrome Foundation, Beverly Hills, MI, USA; 4Department of Medical Education, University of Michigan, Medical School, Ann Arbor, MI, USA; 5Hematology-Oncology, Global Health Economics, Amgen Inc, Thousand Oaks, CA, USA
Purpose: Beginning in 1993 at a single chronic fatigue syndrome (CFS) treatment center, we began studies that demonstrate Epstein–Barr virus (EBV) nonpermissive replication. In the most recent study performed, EBV nonpermissive replication is the cause of 28.3% of 106 consecutive CFS cases, and is etiologic with human cytomegalovirus (HCMV) and/or human herpes virus 6 (HHV-6) as a coinfection in an additional 52.8% of CFS cases. Therefore, EBV is causally involved in 81% of cases of CFS. Further, EBV CFS is effectively treated with long-term valacyclovir. Coinfection HCMV and HHV-6 CFS requires valganciclovir with valacyclovir.
Patients and results: The validated Energy Index Point Score® (EIPS®) monitors severity of CFS illness and its recovery. A specific CFS diagnostic panel identifies EBV CFS subsets. Four separate EBV CFS therapeutic studies of several hundred CFS patients describe valacyclovir (VALTREX) administration and long-term patient recovery. With valacyclovir, serum EBV titers (EBV, early antigen (diffuse); EBV, viral capsid antigen, immunoglobulin M); 24-hour electrocardiography Holter monitors; and cardiac dynamic studies improve.
Conclusion: Nonpermissive EBV infection is causal in a significant proportion of CFS cases. EBV CFS is safely and effectively treated with long-term valacyclovir.
Keywords: valacyclovir (VALTREX) treatment, chronic fatigue syndrome, Epstein–Barr virus, EIPS, Energy Index Point Score
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Other articles by Dr Ann Cavanagh
Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome
22.9.10
MAYO CLINIC: DIAGNOSIS of PRIMARY ALDOSTERONISM
Primary Aldosteronism: The Role of Adrenal Venous Sampling
The triad of hypertension, hypokalemia, and an aldosterone-producing adenoma (APA) of the adrenal gland was first reported by Jerome W. Conn, M.D., in 1955.
Unilateral adrenalectomy in patients with an adrenal adenoma normalizes hypokalemia in all patients, normalizes blood pressure in at least a third of patients, and improves hypertension in nearly all patients.
In patients with idiopathic hyperaldosteronism (IHA), however, a unilateral or bilateral adrenalectomy seldom corrects hypertension. Patients with IHA should be treated not surgically but medically with a mineralocorticoid receptor antagonist.(BLOG: ALDACTONE spironolactone). Therefore, determining the subtype of primary aldosteronism (PA), APA vs IHA, is critical in directing treatment.
Distinguishing between APA and IHA
Selective adrenal venous sampling (AVS) for aldosterone was first proposed in 1967 as a test to distinguish between APA and IHA. However, it is an invasive and difficult technique, and both adrenal veins must be sampled for meaningful comparison.
Computed tomography (CT) was initially thought to be a good test to distinguish among the subtypes of PA. Because of the prevalence of nonfunctioning cortical adenomas, however, hormonal hyperfunction cannot be inferred simply from the presence of an adrenal nodule. Additionally, APAs that are 3 or 4 mm in diameter may escape detection on CT, and patients with a unilateral APA may have bilateral adrenal nodules on CT—one that is nonfunctional and one that is hypersecreting aldosteron
An algorithmic approach to subtype evaluation of a patient with primary aldosteronism helps determine when AVS is needed in patients with PA. Because adrenal incidentalomas are uncommon in young patients, when a solitary unilateral macronodule (>1 cm) and a normal contralateral adrenal are found on CT in a patient with PA, unilateral adrenalectomy is reasonable to consider. In addition, many patients prefer pharmacologic therapy and, therefore, do not require AVS. Using this approach, AVS is done in approximately 20% of patients with PA at Mayo Clinic.
Patients with an APA have more severe hypertension, more frequent hypokalemia, higher plasma (>25 ng/dL) and urinary (>30 μg/24 h) levels of aldosterone, and are younger than those with IHA. Patients with these findings are considered to have a high probability of APA. These findings, however, are not absolute predictors of unilateral (vs bilateral) adrenal disease. Therefore, AVS is an essential diagnostic step in most patients with PA, to distinguish between unilateral and bilateral adrenal aldosterone hypersecretion.
During the procedure, the adrenal veins are sequentially catheterized through the percutaneous femoral vein approach under fluoroscopic guidance, and correct catheter tip location is confirmed with injection of a small amount of contrast medium. Blood is obtained by gentle aspiration from both adrenal veins.
Successful catheterization may require an array of catheter configurations, either available from manufacturers or custom-made with steam shaping during the procedure to facilitate access to the adrenal veins. The placement of side holes very close to the catheter tip may enhance the progress of the blood draw.
At centers with experience with AVS, the complication rate is 2.5% or less. Complications may include:
* Symptomatic groin hematoma
* Adrenal hemorrhage
* Dissection of an adrenal vein
Aldosterone and cortisol concentrations are measured in the blood from all 3 sites (right adrenal vein, left adrenal vein, and inferior vena cava). All blood samples should be assayed at 1:1, 1:10, and 1:50 dilutions—absolute values are mandatory. Accurate laboratory assays for cortisol and aldosterone are keys to successful interpretation of the AVS data.
Mayo Clinic has now performed AVS in more than 400 patients. For patients with PA who want to pursue the surgical treatment option, AVS is an essential diagnostic step.
* Primary aldosteronism (PA) affects between 5% and 10% of all patients with hypertension.
* PA has more than one cause, and most patients with PA have bilateral idiopathic hyperaldosteronism (IHA).
* Because patients with IHA should be treated medically not surgically, distinguishing between aldosterone-producing adenoma (APA) and IHA is critical in directing treatment.
* For patients with PA who want to pursue the surgical treatment option, adrenal venous sampling (AVS) is an essential diagnostic step.
In a 37-year-old woman with poorly controlled hypertension and primary aldosteronism who had a CT scan and AVS radiographs: The cortisol concentrations from the adrenal veins and inferior vena cava are used to confirm successful catheterization; the ratio of adrenal vein cortisol to inferior vena cava is typically more than 10:1 when the protocol for continuous cosyntropin infusion is followed. Dividing the plasma aldosterone concentrations (PACs) of the right and left adrenal veins by the respective cortisol concentrations corrects for the dilutional effect of blood from the inferior phrenic vein flowing into the left adrenal vein; these quotients are termed cortisol-corrected aldosterone ratios. In patients with aldosterone-producing adenoma (APA), the mean cortisol-corrected aldosterone ratio (the ratio of APA-side PAC/cortisol concentration to normal adrenal PAC/cortisol concentration) is 18:1. A cutoff for the cortisol-corrected aldosterone ratio from high side to low side of more than 4:1 is used to indicate unilateral aldosterone excess. The lateralization ratio in this patient of 20.5:1 is consistent with a right adrenal APA.
The triad of hypertension, hypokalemia, and an aldosterone-producing adenoma (APA) of the adrenal gland was first reported by Jerome W. Conn, M.D., in 1955.
Unilateral adrenalectomy in patients with an adrenal adenoma normalizes hypokalemia in all patients, normalizes blood pressure in at least a third of patients, and improves hypertension in nearly all patients.
In patients with idiopathic hyperaldosteronism (IHA), however, a unilateral or bilateral adrenalectomy seldom corrects hypertension. Patients with IHA should be treated not surgically but medically with a mineralocorticoid receptor antagonist.(BLOG: ALDACTONE spironolactone). Therefore, determining the subtype of primary aldosteronism (PA), APA vs IHA, is critical in directing treatment.
Distinguishing between APA and IHA
Selective adrenal venous sampling (AVS) for aldosterone was first proposed in 1967 as a test to distinguish between APA and IHA. However, it is an invasive and difficult technique, and both adrenal veins must be sampled for meaningful comparison.
Computed tomography (CT) was initially thought to be a good test to distinguish among the subtypes of PA. Because of the prevalence of nonfunctioning cortical adenomas, however, hormonal hyperfunction cannot be inferred simply from the presence of an adrenal nodule. Additionally, APAs that are 3 or 4 mm in diameter may escape detection on CT, and patients with a unilateral APA may have bilateral adrenal nodules on CT—one that is nonfunctional and one that is hypersecreting aldosteron
An algorithmic approach to subtype evaluation of a patient with primary aldosteronism helps determine when AVS is needed in patients with PA. Because adrenal incidentalomas are uncommon in young patients, when a solitary unilateral macronodule (>1 cm) and a normal contralateral adrenal are found on CT in a patient with PA, unilateral adrenalectomy is reasonable to consider. In addition, many patients prefer pharmacologic therapy and, therefore, do not require AVS. Using this approach, AVS is done in approximately 20% of patients with PA at Mayo Clinic.
Patients with an APA have more severe hypertension, more frequent hypokalemia, higher plasma (>25 ng/dL) and urinary (>30 μg/24 h) levels of aldosterone, and are younger than those with IHA. Patients with these findings are considered to have a high probability of APA. These findings, however, are not absolute predictors of unilateral (vs bilateral) adrenal disease. Therefore, AVS is an essential diagnostic step in most patients with PA, to distinguish between unilateral and bilateral adrenal aldosterone hypersecretion.
During the procedure, the adrenal veins are sequentially catheterized through the percutaneous femoral vein approach under fluoroscopic guidance, and correct catheter tip location is confirmed with injection of a small amount of contrast medium. Blood is obtained by gentle aspiration from both adrenal veins.
Successful catheterization may require an array of catheter configurations, either available from manufacturers or custom-made with steam shaping during the procedure to facilitate access to the adrenal veins. The placement of side holes very close to the catheter tip may enhance the progress of the blood draw.
At centers with experience with AVS, the complication rate is 2.5% or less. Complications may include:
* Symptomatic groin hematoma
* Adrenal hemorrhage
* Dissection of an adrenal vein
Aldosterone and cortisol concentrations are measured in the blood from all 3 sites (right adrenal vein, left adrenal vein, and inferior vena cava). All blood samples should be assayed at 1:1, 1:10, and 1:50 dilutions—absolute values are mandatory. Accurate laboratory assays for cortisol and aldosterone are keys to successful interpretation of the AVS data.
Mayo Clinic has now performed AVS in more than 400 patients. For patients with PA who want to pursue the surgical treatment option, AVS is an essential diagnostic step.
* Primary aldosteronism (PA) affects between 5% and 10% of all patients with hypertension.
* PA has more than one cause, and most patients with PA have bilateral idiopathic hyperaldosteronism (IHA).
* Because patients with IHA should be treated medically not surgically, distinguishing between aldosterone-producing adenoma (APA) and IHA is critical in directing treatment.
* For patients with PA who want to pursue the surgical treatment option, adrenal venous sampling (AVS) is an essential diagnostic step.
In a 37-year-old woman with poorly controlled hypertension and primary aldosteronism who had a CT scan and AVS radiographs: The cortisol concentrations from the adrenal veins and inferior vena cava are used to confirm successful catheterization; the ratio of adrenal vein cortisol to inferior vena cava is typically more than 10:1 when the protocol for continuous cosyntropin infusion is followed. Dividing the plasma aldosterone concentrations (PACs) of the right and left adrenal veins by the respective cortisol concentrations corrects for the dilutional effect of blood from the inferior phrenic vein flowing into the left adrenal vein; these quotients are termed cortisol-corrected aldosterone ratios. In patients with aldosterone-producing adenoma (APA), the mean cortisol-corrected aldosterone ratio (the ratio of APA-side PAC/cortisol concentration to normal adrenal PAC/cortisol concentration) is 18:1. A cutoff for the cortisol-corrected aldosterone ratio from high side to low side of more than 4:1 is used to indicate unilateral aldosterone excess. The lateralization ratio in this patient of 20.5:1 is consistent with a right adrenal APA.
27.8.10
London, UK PRIMAL PICTURES Ltd. On-Line 3D Anatomical Atlas.
www.primalpictures.com
DIGITAL 3D anatomy and clinical titles from PRIMAL PICTURES.
DIGITAL 3D anatomy and clinical titles from PRIMAL PICTURES.
ASTRA TECH AB : LoFric Sense hydrophilic urinary catheter
Urotonic™ Surface Technology
LoFric® – the first hydrophilic urinary catheter – was introduced more than 25 years ago.
Being hydrophilic means that the catheter's surface layer has a special coating that binds water and creates a very wet and slippery surface, in principle frictionless during insertion.
Today there are several hydrophilic catheters on the market, but there are important differences between LoFric and the others. The secret behind LoFric is the Urotonic™ Surface Technology (UST).
Essentially, Urotonic™ Surface Technology binds water to the catheter tube. This creates a wet and slippery surface that reduces friction against the urethra by 90-95% compared to a regular catheter with gel.
This allows the catheter to slide in and out of the urethra in the most comfortable way possible. And, just as importantly, there's less risk of long-term complications from the repeated friction of self-catheterising.
Now on sale in CANADA.(NOT covered by Ontario Insurance plan).
www.lofricsense.com
LoFric® – the first hydrophilic urinary catheter – was introduced more than 25 years ago.
Being hydrophilic means that the catheter's surface layer has a special coating that binds water and creates a very wet and slippery surface, in principle frictionless during insertion.
Today there are several hydrophilic catheters on the market, but there are important differences between LoFric and the others. The secret behind LoFric is the Urotonic™ Surface Technology (UST).
Essentially, Urotonic™ Surface Technology binds water to the catheter tube. This creates a wet and slippery surface that reduces friction against the urethra by 90-95% compared to a regular catheter with gel.
This allows the catheter to slide in and out of the urethra in the most comfortable way possible. And, just as importantly, there's less risk of long-term complications from the repeated friction of self-catheterising.
Now on sale in CANADA.(NOT covered by Ontario Insurance plan).
www.lofricsense.com
25.8.10
MEDIWATCH Ltd PSAwatch point-of-care test
www.mediwatch.com
UK PSAwatch with BIOSCAN reader system uses finger-prick blood for 10 min. PSA` test.
UK PSAwatch with BIOSCAN reader system uses finger-prick blood for 10 min. PSA` test.
20.8.10
ANGIOPOIETIN.de
Welcome to angiopoietin.de.
This site contains information about the role of the Angiopoietin-Tie2 ligand-receptor system in health and disease.
Our initiative is to create an address for everyone who needs information about angiopoietins. You're welcome to post results of you research concerning angiopoietins and related topics. Enjoy your stay on angiopoietin.de. Feel free to contact us for any questions or remarks by sending a mail.
 |  |
17.8.10
RADIO FREQUENCY ID in HOSPITALS
These applications can be combined with ActiveWave access control to allow only authorized personnel to access to critical areas of the hospital.
Benefits of using ActiveWave RFID Systems:
- Continuously track each patient's location
- Track the location of doctors and nurses in the hospital
- Track the location of expensive and critical instruments and equipment
- Restrict access to drugs, pediatrics, and other high-threat areas to authorized staff
- Monitor and track unauthorized persons who are loitering around high-threat areas
- Facilitate triage processes by restricting access to authorized staff and "approved" patients during medical emergencies, epidemics, terrorist threats, and other times when demands could threaten the hospital's ability to effectively deliver services
- Use the patient's RFID tag to access patient information for review and update through a hand-held computer
7.8.10
NOISE INDUCED HEARING LOSS
Use BILSOM 303 disposable noise protectors.
WELCH-ALLYN hand-held combined otoscope and audiometer;the AUDIOSCOPE 3 screening audiometer,(includes 4,000 Hz.)
Biophysicist,(Nobel Prize 1961),Geog von BEKESY,(1899-1972),patient- controlled AUTOMATED AUDIOMETER is easy to use in Primary practice. Eliminates any language problem and false patient response.
WELCH-ALLYN hand-held combined otoscope and audiometer;the AUDIOSCOPE 3 screening audiometer,(includes 4,000 Hz.)
Biophysicist,(Nobel Prize 1961),Geog von BEKESY,(1899-1972),patient- controlled AUTOMATED AUDIOMETER is easy to use in Primary practice. Eliminates any language problem and false patient response.
2.8.10
SWISS HIRSLANDEN PRIVATE HOSPITAL GROUP;
HIRSLANDEN PRIVATE HOSPITAL GROUP
http://www.hirslanden.ch/en/privatklinikgruppe/
Neuropelveology, which literally means «the study of pelvic nerves», focuses on diseases and functional disturbances on nerves of the small pelvis.
What is Neuropelveology?
Neuropelveology is a specialized medical domain that focuses on neurological diseases and functional disturbances of the small pelvis. Its diagnostic and therapeutic spectrum is very large. It includes conditions such as endometriosis, tumours of the small pelvis and postoperative scars and adhesions that may affect the small pelvis nerves and cause pain. Neuropelveology also studies direct damage to pelvic nerves that occurs, for example, in multiple sclerosis and spina bifida, as well as traumatic spinal cord lesions and nerve wounds caused by extensive surgery. The diagnosis and targeted therapy of pelvic pain and functional disturbances of the small pelvis require specific medical knowledge in gynaecology, urology, neurology and neurosurgery.
Neuropelveology is typically concerned with the following issues:
* Anatomy (structure and ultrastructure) of the nerves of the small pelvis and preserving this anatomy in the event of radical surgery in order to maintain organ function as far as possible. Thus, in the case of endometriosis surgery, hysterectomy, prostatectomy or tumour resection, care must be taken to completely preserve the sexual, vesical and intestinal functions.
* Minimally invasive laparoscopy on the nerves of the small pelvis to treat nerve pain in the abdomen and pelvic cavity
* Diagnosis and treatment of pelvic nerve disorders that may cause functional disturbances and pain
* Diagnosis and treatment of different conditions of the small pelvis that are not necessarily neurological but nevertheless result in pelvic nerve pain or disorders.
http://www.hirslanden.ch/en/privatklinikgruppe/
Neuropelveology, which literally means «the study of pelvic nerves», focuses on diseases and functional disturbances on nerves of the small pelvis.
What is Neuropelveology?
Neuropelveology is a specialized medical domain that focuses on neurological diseases and functional disturbances of the small pelvis. Its diagnostic and therapeutic spectrum is very large. It includes conditions such as endometriosis, tumours of the small pelvis and postoperative scars and adhesions that may affect the small pelvis nerves and cause pain. Neuropelveology also studies direct damage to pelvic nerves that occurs, for example, in multiple sclerosis and spina bifida, as well as traumatic spinal cord lesions and nerve wounds caused by extensive surgery. The diagnosis and targeted therapy of pelvic pain and functional disturbances of the small pelvis require specific medical knowledge in gynaecology, urology, neurology and neurosurgery.
Neuropelveology is typically concerned with the following issues:
* Anatomy (structure and ultrastructure) of the nerves of the small pelvis and preserving this anatomy in the event of radical surgery in order to maintain organ function as far as possible. Thus, in the case of endometriosis surgery, hysterectomy, prostatectomy or tumour resection, care must be taken to completely preserve the sexual, vesical and intestinal functions.
* Minimally invasive laparoscopy on the nerves of the small pelvis to treat nerve pain in the abdomen and pelvic cavity
* Diagnosis and treatment of pelvic nerve disorders that may cause functional disturbances and pain
* Diagnosis and treatment of different conditions of the small pelvis that are not necessarily neurological but nevertheless result in pelvic nerve pain or disorders.
BRYAN-KUNZLER CERVICAL DISC PROTHESIS.
USA FDA approved the BRYAN-KUNZLER CERVICAL DISC device in 2009. Invented by Seattle Neurosurgeon (and fruit grower/vintner) VINCENT E. BRYAN Jr and SWISS-TRAINED Mechanical engineer ALEX KUNZLER in 1993. First used in BEGIUM in 2000 by UZ GASTHUISBERG ,LEUVEN Neurosurgeon JAN GOFFIN. Patent Rights bought by MEDRONIC SOFAMOR DANEK in 2000.
Recent research/review paper by SWISS Neurosurgeons M.WENGER & T.MARKWALDER of KLINIK BEAU-SITE, BERNE; member of HIRSLANDEN HOSPITAL GROUP, owned by UK BUPA.
aerzte.beau-site@hirslanden.ch
Recent research/review paper by SWISS Neurosurgeons M.WENGER & T.MARKWALDER of KLINIK BEAU-SITE, BERNE; member of HIRSLANDEN HOSPITAL GROUP, owned by UK BUPA.
aerzte.beau-site@hirslanden.ch
25.7.10
EOS(Gr.DAWN) & sterEOS :ultra low dose X-ray system.
Based on invention of 1992 Nobel PHYSICS Prize winner, Polish-born, WW2 French Resistance fighter, DACHAU survivor, George CHARPAK who worked with Paris Paediatric Orthopaedic surgeon Professor Jean DUBOUSSET MD PhD.
Whole-body three dimensional speedy imaging. $700,000. Used at Toronto Hospital for Sick Children and Univ. Montreal St.JUSTINE & McGill SHRINERS'.
www.biospacemed.com
CONTACT: Mr.M. MAASSEN mmaassen@biospacemed.com
Whole-body three dimensional speedy imaging. $700,000. Used at Toronto Hospital for Sick Children and Univ. Montreal St.JUSTINE & McGill SHRINERS'.
www.biospacemed.com
CONTACT: Mr.M. MAASSEN mmaassen@biospacemed.com
24.7.10
enSPIRE DISCECTOMY & DECORTICATION System
SPINE VIEW Inc.,Fremont,California. DISPOSABLE. Simultaneously cuts and removes disc material including endplate cartilage
www.spineview.com
.
www.spineview.com
.
23.7.10
SPINEGUARD S.A.: PediGuard - electrical audio device detects vertebral cortex.
TORONTO Scoliosis Research Society meeting:
SPINEGUARD S.A. exhibited PEDIGUARD which changes audio signal when pedicle screw placer touches CORTICAL bone.
Invented by Neurosurgeon Ciaran BOLGER & Engineer Maurice BOURLION.in 2006.
.
SPINEGUARD S.A. exhibited PEDIGUARD which changes audio signal when pedicle screw placer touches CORTICAL bone.
Invented by Neurosurgeon Ciaran BOLGER & Engineer Maurice BOURLION.in 2006.
.
ALPHATEC SPINE Inc. HeliFix TM Interspinous Spacer System
SCOLIOSIS RESEARCH SOCIETY at TORONTO Sheraton Center.
ALPHATEC SPINE Inc.,CARLSBAD,California showed the HeliFix TM Interspinous Spacer at $2,000.
Developed by YALE ORTHOPAEDIC & REHABILITATION Assoc.PROF.James YUE BA(Harvard) MD(Northwestern 1992)
To be launched at EUROSPINE, VIENNA, Sept. 2010.
ALPHATEC SPINE Inc.,CARLSBAD,California showed the HeliFix TM Interspinous Spacer at $2,000.
Developed by YALE ORTHOPAEDIC & REHABILITATION Assoc.PROF.James YUE BA(Harvard) MD(Northwestern 1992)
To be launched at EUROSPINE, VIENNA, Sept. 2010.
8.7.10
HOFFMANN-LaROCHE extRA Mt.SINAI International Conference.
2010,July 8-9.
F.HOFFMANN-La ROCHE Ltd. sponsored a UK Manchester-organized "extRA" International meeting of about 50 Rheumatologists at Toronto Mt.Sinai hospital's,Joseph & Wolf Lebovic building; including doctors from the Gulf States, Ireland, Poland,Taiwan,Turkey,and UK. The meeting was held in the $4-million luxuriously appointed 7,000 sq.ft.REBECCA MacDONALD ARTHRITIS & AUTOIMMUNE DISEASE CENTER in the LEBOVIC building. The MacDONALD, under the Director U.Toronto Prof. Edward C.KEYSTONE MD(Tor.63) FRCPC(1968),is a Tertiary Arthritis Centre similar to the London,UK KENNEDY Institute. The MacDONALD specializes in Rheumatoid Arthritis , Rheumatoid Vasculitis,and Systemic Lupus Erythematosus. Patients are accepted worldwide. Canadian provincial medical insurances pay cost of provincially-approved medications and medical expenses.
Other speakers included Toronto Western Hospital Prof. Murray UROWITZ MD(Tor.1963)FRCPC(1968,)and Prof. Simon CARETTE MD(Laval.1975), MPhil. FRCPC(1980); and St.Michael's Hospital Dept. Rheum. Clin. Assoc.Dr.Shahin JAMAL MD(UBC 1999) MSc(Epid) FRCPC(2003)
F.HOFFMANN-La ROCHE Ltd. sponsored a UK Manchester-organized "extRA" International meeting of about 50 Rheumatologists at Toronto Mt.Sinai hospital's,Joseph & Wolf Lebovic building; including doctors from the Gulf States, Ireland, Poland,Taiwan,Turkey,and UK. The meeting was held in the $4-million luxuriously appointed 7,000 sq.ft.REBECCA MacDONALD ARTHRITIS & AUTOIMMUNE DISEASE CENTER in the LEBOVIC building. The MacDONALD, under the Director U.Toronto Prof. Edward C.KEYSTONE MD(Tor.63) FRCPC(1968),is a Tertiary Arthritis Centre similar to the London,UK KENNEDY Institute. The MacDONALD specializes in Rheumatoid Arthritis , Rheumatoid Vasculitis,and Systemic Lupus Erythematosus. Patients are accepted worldwide. Canadian provincial medical insurances pay cost of provincially-approved medications and medical expenses.
Other speakers included Toronto Western Hospital Prof. Murray UROWITZ MD(Tor.1963)FRCPC(1968,)and Prof. Simon CARETTE MD(Laval.1975), MPhil. FRCPC(1980); and St.Michael's Hospital Dept. Rheum. Clin. Assoc.Dr.Shahin JAMAL MD(UBC 1999) MSc(Epid) FRCPC(2003)
7.7.10
Drug Resistant P.FALCIPARUM MALARIA: TANZANIA
Actress Cheryl COLE, who took anti-malarial medication during a holiday in TANZANIA, is now transferred from London,UK Bupa CROMWELL HOSPITAL to intensive care unit of the HOSPITAL for TROPICAL DISEASES near Euston Tube station.
http://www.cdc.gov/malaria/resources/pdf/algorithm.pdf
Excellent algorithm for diagnosis,investigation & treatment of MALARIA.
http://www.cdc.gov/malaria/resources/pdf/algorithm.pdf
Excellent algorithm for diagnosis,investigation & treatment of MALARIA.
1.7.10
UK MADE: KEELER PORTABLE SLIT LAMP
Features
* Precision machined aluminum chassis
* Advanced optics, x10 & x16 magnification
* Controllable illumination from maximum to zero
* Big Slit Lamp features, portable usability
British engineering. British manufacturing. British quality...and legendary Keeler performance.
Keeler PSL Classic Portable Slit Lamp
Keeler PSL Classic Portable Slit Lamp
$4,250.00 reduced to $3,995.00
* Precision machined aluminum chassis
* Advanced optics, x10 & x16 magnification
* Controllable illumination from maximum to zero
* Big Slit Lamp features, portable usability
British engineering. British manufacturing. British quality...and legendary Keeler performance.
Keeler PSL Classic Portable Slit Lamp
Keeler PSL Classic Portable Slit Lamp
$4,250.00 reduced to $3,995.00
23.6.10
FREE ARRHYTHMIA GENETIC SCREENING by MASONIC MEDICAL RESEARCH LAB.
The Molecular Genetics Program at the Masonic Medical Research Laboratory has assembled a team of investigators capable of streamlining the approach to genetic screening and subsequent functional in vitro analysis of ion channel mutations linked to inherited cardiac arrhythmia and conduction disease. We are certified as a CLIA/CLEP-approved clinical laboratory by the New York State Department of Health.
We invite your participation and collaboration in these projects. We are particularly interested in individuals, or preferably, large families with any of the following:
» Brugada Syndrome
Spontaneous Brugada ECG phenotype
Brugada phenotype unmasked or induced by sodium channel blockers, hormonal imbalances
pheochromocytoma,antidepressant or other drugs, hyponatremia or other electrolyte imbalances,
alcohol, vagotonic agents or vagal, maneuvers (including full stomach).
» Familial Atrial Fibrillation
» Catecholamine-sensitive VT
» Non-ischemia-related VT/VF occurring in young individuals
» Post-MI QT prolongation and Torsade de Pointes
» Progressive Conduction Disease
» Sudden death in infants and children (including SIDS)
» Acquired Long QT Syndrome (Congenital LQTS cases should be referred to familion or other commercial testing facilities)
» Short QT Syndrome
Please do not hesitate to contact us regarding these or other familial arrhythmic syndromes. Should a new mutation or gene be uncovered as a result of genetic screen of the DNA samples provided, the submitting physician will be included as a co-author.
Blood Collection and Delivery: Instruction for collection and delivery of blood can be found at Blood Collection and Delivery Instructions.
Informed Consent Forms: We will require you to obtain informed consent from each patient selected for participation in the study. Informed consent forms can be found at Informed Consent Forms 1 and 2 .Patient must sign both in order for us to proceed with both Clinical Diagnosis and Research Protocols.
Clinical History and ECGs: You will also be required to fill out a clinical history form, which can be found at Clinical History Form and provide us with ECGs supporting the diagnosis.
An authorization number for submission of blood/DNA will be issued once the clinical data are reviewed.Blood/DNA will not be accepted for processing without an authorization number.
Contact Information: Please address all inquiries to genetics@mmrl.edu or Tel : 315-735-2217 ext:119
We invite your participation and collaboration in these projects. We are particularly interested in individuals, or preferably, large families with any of the following:
» Brugada Syndrome
Spontaneous Brugada ECG phenotype
Brugada phenotype unmasked or induced by sodium channel blockers, hormonal imbalances
pheochromocytoma,antidepressant or other drugs, hyponatremia or other electrolyte imbalances,
alcohol, vagotonic agents or vagal, maneuvers (including full stomach).
» Familial Atrial Fibrillation
» Catecholamine-sensitive VT
» Non-ischemia-related VT/VF occurring in young individuals
» Post-MI QT prolongation and Torsade de Pointes
» Progressive Conduction Disease
» Sudden death in infants and children (including SIDS)
» Acquired Long QT Syndrome (Congenital LQTS cases should be referred to familion or other commercial testing facilities)
» Short QT Syndrome
Please do not hesitate to contact us regarding these or other familial arrhythmic syndromes. Should a new mutation or gene be uncovered as a result of genetic screen of the DNA samples provided, the submitting physician will be included as a co-author.
Blood Collection and Delivery: Instruction for collection and delivery of blood can be found at Blood Collection and Delivery Instructions.
Informed Consent Forms: We will require you to obtain informed consent from each patient selected for participation in the study. Informed consent forms can be found at Informed Consent Forms 1 and 2 .Patient must sign both in order for us to proceed with both Clinical Diagnosis and Research Protocols.
Clinical History and ECGs: You will also be required to fill out a clinical history form, which can be found at Clinical History Form and provide us with ECGs supporting the diagnosis.
An authorization number for submission of blood/DNA will be issued once the clinical data are reviewed.Blood/DNA will not be accepted for processing without an authorization number.
Contact Information: Please address all inquiries to genetics@mmrl.edu or Tel : 315-735-2217 ext:119
22.6.10
LONDON SCHOOL of HYGIENE & TROPICAL MEDICINE
http://www.lshtm.ac.uk/prospectus/short
ON-LINE short courses:
TRAVEL MEDICINE $300
EPIDEMIOLOGY: $100
ON-LINE short courses:
TRAVEL MEDICINE $300
EPIDEMIOLOGY: $100
15.6.10
FREE HEALTH SAFETY WATCH
www.healthandsafetywatch.com
519-265-3851
Dr Jeff ARAMINI DVM(Guelph) MSc. PhD(Guelph Epidemiology)
Pres/CEO INTELLIGENT HEALTH SOLUTIONS Inc.
HEALTH & SAFETY WATCH Inc.
MONITORS MEDICAL & ENVIRONMENTAL DANGERS in Canadian GEOGRAPHIC AREAS.
FREE
519-265-3851
Dr Jeff ARAMINI DVM(Guelph) MSc. PhD(Guelph Epidemiology)
Pres/CEO INTELLIGENT HEALTH SOLUTIONS Inc.
HEALTH & SAFETY WATCH Inc.
MONITORS MEDICAL & ENVIRONMENTAL DANGERS in Canadian GEOGRAPHIC AREAS.
FREE
5.6.10
PROVENGE (sipuleucel-T) : DENDREON Corp.
ACTIVE CELLULAR IMMUNOTHERAPY)
www.dendreon.com
Dendreon Corporation (Nasdaq: DNDN) announced the presentation of safety data from the integrated analysis of four randomized PROVENGE(R) (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.
"The approval of PROVENGE provides us with an important new, front-line option for men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer," said Simon Hall, M.D., director of the Barbara and Maurice Deane Prostate Health and Research Center at Mount Sinai Medical Center."
Extended life by average 4.1 months at cost of US$93,000 for 3 dose treatment.
Pres./CEO/Dir. Dr.MITCHELL GOLD MD(Rush,Chicago) Urology resident U.Washington.
Med. Informatics expert.
Sr.V-P.Dr.MARK FROLICH BS(YALE-engineering/economics) MD (HARVARD) past Asst.Prof U.Cal.(San Fran)UROLOGICAL ONCOLOGY
www.dendreon.com
Dendreon Corporation (Nasdaq: DNDN) announced the presentation of safety data from the integrated analysis of four randomized PROVENGE(R) (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.
"The approval of PROVENGE provides us with an important new, front-line option for men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer," said Simon Hall, M.D., director of the Barbara and Maurice Deane Prostate Health and Research Center at Mount Sinai Medical Center."
Extended life by average 4.1 months at cost of US$93,000 for 3 dose treatment.
Pres./CEO/Dir. Dr.MITCHELL GOLD MD(Rush,Chicago) Urology resident U.Washington.
Med. Informatics expert.
Sr.V-P.Dr.MARK FROLICH BS(YALE-engineering/economics) MD (HARVARD) past Asst.Prof U.Cal.(San Fran)UROLOGICAL ONCOLOGY
ANNIDIS RHA
ANNIDIS RHA measures RETINAL HEALTH
www.annidis.com see links on ANNIDIS Google.
Invented and made in CANADA.
Developed in OTTAWA at ANNIDIS Health systems Corp. by Dr. BRIAN LEONARD MD(Ottawa 1970) FRCS(C) who did a Fellowship at Philadelphia's WILLS EYE INSTITUTE in RETINOVITREOUS diseases.
Not yet USA approved.
www.annidis.com see links on ANNIDIS Google.
Invented and made in CANADA.
Developed in OTTAWA at ANNIDIS Health systems Corp. by Dr. BRIAN LEONARD MD(Ottawa 1970) FRCS(C) who did a Fellowship at Philadelphia's WILLS EYE INSTITUTE in RETINOVITREOUS diseases.
Not yet USA approved.
24.4.10
ESAOTE(S-A-O-T) MOBILE ULTRASOUND
ESAOTE mobile (carrier case) model MyLabFive at $25,000 shown at recent Toronto American Association Neurology and American Anaesthesia conferences.
ESAOTE: 1986 union of Elsag,Selenia,Ansaldo(ESA CONTROL) and OTE Medical, (Officine Toscane Elettromeccanico).
ESAOTE one of four companies held by Swiss ARES LIFE SCIENCES (Zug & Geneva)
ESAOTE: 1986 union of Elsag,Selenia,Ansaldo(ESA CONTROL) and OTE Medical, (Officine Toscane Elettromeccanico).
ESAOTE one of four companies held by Swiss ARES LIFE SCIENCES (Zug & Geneva)
13.4.10
ACTHAR GEL: (repository corticotrophin injection)
ACTHAR GEL 80 units / ml extracted from Pig pituitary ( QUESTCOR Pharmaceuticals Inc.) available again in Canada. Price $5,000 per ml. (In 1980s was FIVE DOLLARS per ml supplied by ARMOUR.)
Used mainly for acute Multiple sclerosis at 1 ml. daily by IMI for two weeks at cost of $70,000.
Used mainly for acute Multiple sclerosis at 1 ml. daily by IMI for two weeks at cost of $70,000.
ANDERSON-FABRY DISEASE
William ANDERSON (1842-1900) UK Artist & Surgeon & Johannes FABRY (1860-1930) German Dermatologist.
FABRAZYME (agalsidase beta) GENZYME Canada; IMI every two weeks costs $200,000 a year. Approved for payment by Ontario government in 2004.
FABRAZYME (agalsidase beta) GENZYME Canada; IMI every two weeks costs $200,000 a year. Approved for payment by Ontario government in 2004.
29.3.10
Prof. MOLLY SHOICHET PhD FRSC
University Toronto Professor of Biochemical engineering Molly SHOICHET is the only Canadian of the 16 invited speakers to the 2010 ROCHE-NATURE MEDICINE Swiss conference on TRANSLATIONAL NEUROSCIENCE.
Dr. Molly Shoichet holds the NSERC Canada Research Chair in Tissue Engineering and is Professor of Chemical Engineering & Applied Chemistry, Chemistry and Biomaterials & Biomedical Engineering at the University of Toronto. She is an expert in the study of Polymers for Regeneration which are materials that promote healing in the body. Dr. Shoichet's laboratory has numerous patents (published and pending) on drug delivery and scaffold design. She has founded two spin-off companies from her laboratory. Before being recruited to the University of Toronto in 1995, Dr. Shoichet worked at CytoTherapeutics Inc. on encapsulated cell therapy. Dr. Shoichet is the recipient of such prestigious distinctions as NSERC's Steacie Fellowship, CIHR's Young Explorer's Award (to the top 20 scientists under 40 in Canada), CSChE's Syncrude Innovation Award, Canada's Top 40 under 40 and the Royal Society of Canada's Rutherford Memorial Award. Dr. Shoichet received her S.B. from the Massachusetts Institute of Technology in Chemistry (1987) and her Ph.D. from the University of Massachusetts, Amherst in Polymer Science and Engineering (1992). She has published over 290 papers, patents and abstracts.
(A Shoichet is a Kosher Butcher)
Dr. Molly Shoichet holds the NSERC Canada Research Chair in Tissue Engineering and is Professor of Chemical Engineering & Applied Chemistry, Chemistry and Biomaterials & Biomedical Engineering at the University of Toronto. She is an expert in the study of Polymers for Regeneration which are materials that promote healing in the body. Dr. Shoichet's laboratory has numerous patents (published and pending) on drug delivery and scaffold design. She has founded two spin-off companies from her laboratory. Before being recruited to the University of Toronto in 1995, Dr. Shoichet worked at CytoTherapeutics Inc. on encapsulated cell therapy. Dr. Shoichet is the recipient of such prestigious distinctions as NSERC's Steacie Fellowship, CIHR's Young Explorer's Award (to the top 20 scientists under 40 in Canada), CSChE's Syncrude Innovation Award, Canada's Top 40 under 40 and the Royal Society of Canada's Rutherford Memorial Award. Dr. Shoichet received her S.B. from the Massachusetts Institute of Technology in Chemistry (1987) and her Ph.D. from the University of Massachusetts, Amherst in Polymer Science and Engineering (1992). She has published over 290 papers, patents and abstracts.
(A Shoichet is a Kosher Butcher)
28.3.10
TOP POSTDOC INTERNATIONAL INSTITUTIONS.
http://www.the-scientist.com/fragments/bptw/2010/postdoc/bptw-postdoc-top.jsp
UK: 1,2,3,7
SWEDEN: 4,9
SWITZ: 5,6
PORTUGAL 8
CANADA: 10
PRIVATE MEDICINE provided by NOVARTIS,UK and CAMBRIDGE UNIVERSITY which also includes
a Pension scheme.
UK: 1,2,3,7
SWEDEN: 4,9
SWITZ: 5,6
PORTUGAL 8
CANADA: 10
PRIVATE MEDICINE provided by NOVARTIS,UK and CAMBRIDGE UNIVERSITY which also includes
a Pension scheme.
27.3.10
20th ROTMAN RESEARCH INSTITUTE CONFERENCE
20th ROTMAN INSTITUTE CONFERENCE held in Toronto at Metro Convention Centre.
Organized by Psychologist Univ.Tor.Prof. Donald STUSS O.Ont. PhD,Senior Scientist of the Rotman Research Institute located at the Baycrest Jewish Centre for the Aged and Neurologist Univ. California,(Berkeley),Director,Helen Wills Neuroscience Instiute, Prof. Robert KNIGHT MD.
Keynote Speakers:
Univ.California(Los Angeles), Director,Semel Institute of Neuroscience and Human Behaviour, Prof. Joaquin FUSTER MD Author of The Prefrontal Cortex (4th.Ed.)2008.
Univ.of Parma, Director, Dept. Neuroscience, Neurophysiologist, Prof. Giacomo Rizzolatti MD
http://baycrestberkeley.wordpress.com/2010/03/
Review of meeting.
Organized by Psychologist Univ.Tor.Prof. Donald STUSS O.Ont. PhD,Senior Scientist of the Rotman Research Institute located at the Baycrest Jewish Centre for the Aged and Neurologist Univ. California,(Berkeley),Director,Helen Wills Neuroscience Instiute, Prof. Robert KNIGHT MD.
Keynote Speakers:
Univ.California(Los Angeles), Director,Semel Institute of Neuroscience and Human Behaviour, Prof. Joaquin FUSTER MD Author of The Prefrontal Cortex (4th.Ed.)2008.
Univ.of Parma, Director, Dept. Neuroscience, Neurophysiologist, Prof. Giacomo Rizzolatti MD
http://baycrestberkeley.wordpress.com/2010/03/
Review of meeting.
15.3.10
OVA1:OVARIAN CANCER TEST
Quest Diagnostics Nichols Institute
FDA Approved/Cleared
--------------------------------------------------------------------------------
This test performed at:
Quest Diagnostics Chantilly
Nichols Institute
14225 Newbrook Dr.
Chantilly, VA 20151-2228
NI#: 11836
CONTACT : Phone: (800) 336-3718 at Quest Diagnostics Chantilly
CPT CODES : 84999
PRICES : LIST PRICE $650.00 PATIENT PRICE $650.00
PREFERRED SPECIMEN
SPECIMEN : Serum
VOLUME : Standard: 2.2 mL - Minimum: 1.1 mL **
CONTAINER: No additive (red-top)
SHIP.TEMP: Ship refrigerated
**Volume required to perform single analysis, including instrument dead volume
STABILITY: Room temperature: Unacceptable
Refrigerated: 5 Days
Frozen: 63 Days -70 Degrees: 84 Days
Note: No alternate specimen type available.
INSTRUCTION: No information available
METHOD : Fixed Rate Time Nephelometry and Electrochemiluminescence
SCHEDULE : SETUP DAY/TIME*** REPORT DAY/TIME***
Mon-Sat P
REPORTS 2 DAYS
*** A=6am-12pm, P=12pm-6pm, E=6pm-12am, N(next day)=12am-6am Pacific Time
ADDTL TEMP : Shipping room temp unacceptable; Shipping frozen acceptable
USE : The OVA1(TM) Test is an aid to further assess the likelihood that
ovarian malignancy is present when the physician's independent
clinical and radiological evaluation does not indicate
malignancy.
FDA Approved/Cleared
--------------------------------------------------------------------------------
This test performed at:
Quest Diagnostics Chantilly
Nichols Institute
14225 Newbrook Dr.
Chantilly, VA 20151-2228
NI#: 11836
CONTACT : Phone: (800) 336-3718 at Quest Diagnostics Chantilly
CPT CODES : 84999
PRICES : LIST PRICE $650.00 PATIENT PRICE $650.00
PREFERRED SPECIMEN
SPECIMEN : Serum
VOLUME : Standard: 2.2 mL - Minimum: 1.1 mL **
CONTAINER: No additive (red-top)
SHIP.TEMP: Ship refrigerated
**Volume required to perform single analysis, including instrument dead volume
STABILITY: Room temperature: Unacceptable
Refrigerated: 5 Days
Frozen: 63 Days -70 Degrees: 84 Days
Note: No alternate specimen type available.
INSTRUCTION: No information available
METHOD : Fixed Rate Time Nephelometry and Electrochemiluminescence
SCHEDULE : SETUP DAY/TIME*** REPORT DAY/TIME***
Mon-Sat P
REPORTS 2 DAYS
*** A=6am-12pm, P=12pm-6pm, E=6pm-12am, N(next day)=12am-6am Pacific Time
ADDTL TEMP : Shipping room temp unacceptable; Shipping frozen acceptable
USE : The OVA1(TM) Test is an aid to further assess the likelihood that
ovarian malignancy is present when the physician's independent
clinical and radiological evaluation does not indicate
malignancy.
10.3.10
SMOKESCREEN: GFC DIAGNOSTICS Ltd.
SALIVA & URINE point-of-care tests to detect use of tobacco. 2ml.urine syringe. Saliva sponge collector. Colour indicator.
www.gfcdiagnostics.co.uk
www.gfcdiagnostics.co.uk
3.3.10
IgE ALLERGY BLOOD TESTS
PHADIA (Pharmacia Diagnostics) AB of UPPSALA. Makes auto-analyser for IgE antibody measurement for more than 200 allergens. Uses ISAC (Immuno Solid array chip).
7.2.10
COUNSYL, Inc: SALIVA GENETIC TEST
REDWOOD CITY,California COUNSYL $345 SALIVA test for 100 Genetic diseases. Sold in USA and UK.
30.1.10
PROLASTIN: Alpha1-Proteinase Inhibitor
Congenital Alpha1-antitrypsin deficiency with panacinar emphysema treated with monthly IV injections of PROLASTIN: cost $90,000/year. TALECRIS Biotherapeutics Inc.
Subscribe to:
Posts (Atom)